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ABSTRACT
The development of our understanding of the pharmacokinetic (PK) and pharmacodynamic (PD)
principles that determine antimicrobial efﬁcacy has advanced substantially over the last 10 years. We
are now in a position to use PK ⁄PD principles to set targets for antimicrobial design and optimisation so
that we can predict eradication of speciﬁc pathogens or resistant variants when agents are used
clinically. Optimisation of PK ⁄PD parameters to enable the treatment of resistant pathogens with oral
agents may not be possible with many current agents, such as some cephalosporins, macrolides and
ﬂuoroquinolones. Aminopenicillins, however, such as amoxicillin, have linear PK and have a good
safety proﬁle even at high doses. The new pharmacokinetically enhanced oral formulation of
amoxicillin ⁄ clavulanate, 2000 ⁄ 125 mg twice daily, was designed using PK ⁄PD principles to be able to
eradicate Streptococcus pneumoniae with amoxicillin MICs of up to and including 4 mg ⁄L, which includes
most penicillin-resistant isolates. For amoxicillin and amoxicillin ⁄ clavulanate, a time above MIC
(T > MIC) of 35–40% of the dosing interval (based on blood levels) is predictive of high bacteriological
efﬁcacy. This target was met by the design of a unique bilayer tablet incorporating 437.5 mg of
sustained-release sodium amoxicillin in one layer plus 562.5 mg of immediate-release amoxicillin
trihydrate and 62.5 mg of clavulanate potassium in the second layer, with two tablets administered for
each dose. This unique design extends the bacterial killing time by increasing the T >MIC to 49% of the
dosing interval against pathogens with MICs of 4 mg ⁄L, and 60% of the dosing interval against
pathogens with MICs of 2 mg ⁄L. Based on these results, this new amoxicillin ⁄ clavulanate formulation
should be highly effective in treating respiratory tract infections due to drug-resistant S. pneumoniae as
well as b-lactamase-producing pathogens, such as Haemophilus inﬂuenzae and Moraxella catarrhalis.
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INTRODUCTION
There is no question that the introduction of
antimicrobials to treat bacterial infection has
greatly reduced morbidity and mortality in res-
piratory tract diseases. However, only one pla-
cebo-controlled trial of antimicrobial therapy in
community-acquired pneumonia (CAP), a study
by Evans and Gaisford, published in 1938, is
known to this author [1]. This randomised study
compared one of the initial sulfonamides with
what was, at the time, standard, nonspeciﬁc
supportive treatment in patients who would
now be regarded as having severe disease. Mor-
tality was signiﬁcantly reduced in the patients
receiving sulfonamide (8%) compared with con-
trols (27%) (Fig. 1) [1]. It is also interesting to note
that there was a signiﬁcant effect of age in this
study, with mortality in the control group being
50% in patients 40 years of age or older, com-
pared with 16% in patients under 39 years of age.
Due to the high mortality associated with CAP of
this type, it is no longer considered ethical to
perform placebo-controlled studies, although
milder forms of CAP in outpatients have virtually
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no mortality [2]. Morbidity remains a concern,
however, in CAP, even when the associated risk
of mortality is low, but there is little information
on this subject. Clinical trials that could show a
signiﬁcant difference between antibacterial ther-
apies require very large numbers of patients,
particularly in studies of acute exacerbations of
chronic bronchitis, sinusitis and otitis media,
where rates of spontaneous recovery are high
[3,4]. Thus, the majority of clinical trials are
designed to show only noninferiority of a new
agent compared with existing therapies. The
limitation of this approach is that we have very
little clinical information that can indicate whe-
ther one antibacterial is clinically more effective
than another, or even more effective than placebo.
In fact, statistically similar outcomes between
drugs in a noninferiority trial do not guarantee
equivalency, only that the study was not powered
to show differences in efﬁcacy.
Without a control group against which efﬁcacy
can be judged, it is difﬁcult to evaluate new agents.
Knowledge of the natural history of the disease
being studied is helpful, but in most diseases this is
not fully known, or was determined before the
antibacterial era and so may no longer be relevant.
Antimicrobial resistance to currently used agents
among the key respiratory pathogens is common
world-wide, and theprevalence is increasing [5]. It is
now clear, certainly in CAP [6–8], and also from
double tympanocentesis studies in otitis media
[9–11], that antimicrobial resistance is having a
negative impact on clinical outcomes. Now, more
than ever, it is essential that we knowwhich agents
will have optimal antibacterial efﬁcacy. Moreover,
as resistance increasingly compromises the effect-
iveness of currently available agents, and with a
lack of new agents likely to be available soon, there
is a need to optimise the way in which we use
existing agents.
Until recently, setting breakpoints predictive of
bacterial efﬁcacy was based on in-vitro measures,
such as MIC distributions and inadequate clinical
studies. Over the last decade, however, our
understanding of the relationship between phar-
macokinetics (PK) and pharmacodynamics (PD)
has expanded considerably (see MacGowan, this
issue). PK ⁄PD parameters have been found to
correlate with bacterial and clinical outcomes [12].
We are now in a position where we can use our
greater understanding of PK ⁄PD to direct the
development of new antibacterials and to optim-
ise existing formulations to guide therapy choices
[12–14].
OPTIMISATION OF CURRENTLY
AVAILABLE ANTIBIOTICS USING
PK ⁄ PD
Antibacterials have been shown to have either
time-dependent or concentration-dependent efﬁc-
acy (Table 1) [15–17]. For antimicrobials whose
bacteriological efﬁcacy is time-dependent, the
PK ⁄PD parameter that most closely correlates
with efﬁcacy is the duration of the dosing interval
for which serum concentrations exceed the MIC
(T > MIC) [18]. For drugs with concentration-
dependent killing, the ratio of either the area
under the serum concentration–time curve to the
MIC (AUC:MIC) or the peak serum concentration
to the MIC (Cmax:MIC) are most predictive of
bacteriological efﬁcacy [18]. Once the magnitude
of the PK ⁄PD parameter required for maximal
bacteriological efﬁcacy has been determined, it can
be used to predict whether a given agent will be
effective against pathogens with a given MIC. The
magnitude of the PK ⁄PD parameter needed to
attain maximal antimicrobial efﬁcacy is similar in
animals and humans, therefore animal models can
also be used to predict antimicrobial activity in
humans [18,19]. In addition, double tympanocent-
esis studies in otitis media allow PK ⁄PD pre-
dictions to be veriﬁed clinically, because middle
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ear ﬂuid is obtained for culture before and then 3–
5 days after antimicrobial therapy has started.
Thus, clinically veriﬁed PK ⁄PD targets can be set
for the optimisation of antibacterials, and the
ability of different agents to achieve these targets
can be assessed. The capacity to optimise an
antibacterial based on PK ⁄PD will depend upon
several factors, including the MIC of the target
organism, the PK (and how easy this is to mani-
pulate), as well as the safety proﬁle of the drug.
Macrolides and azalides
Until recently, macrolides were thought to exhibit
time-dependent, and azalides concentration-
dependent, antibacterial activity. Craig and col-
leagues, however, have recently suggested that
bactericidal activity of all macrolides, azalides
and ketolides is concentration-dependent [16]. In
this study, a 24-h AUC:MIC ratio of at least 16.4–
26.4, based on unbound serum concentrations,
was predictive of maximal bacterial eradication
for erythromycin, clarithromycin, 14-hydroxy-
clarithromycin, roxithromycin, azithromycin,
ABT-773, HMR6004 and clindamycin against a
standard strain of Streptococcus pneumoniae. Other
studies, however, have shown erythromycin to be
time-dependent, and azithromycin and clarithro-
mycin to be concentration-dependent, with
Cmax:MIC ratio being the best predictor of activity
[20,21]. Studies such as these allow PK ⁄PD break-
points to be calculated that predict theMIC cut-offs
for maximal bacterial eradication. For example, a
recent study by Hoffman et al. in a mouse model
of pneumococcal pneumonia indicated a PK ⁄PD
breakpoint of 1 mg ⁄L for clarithromycin [22]. This
study showed that after 84 h, survival in mice
treated with doses simulating human PK was
generally ‡ 50% for strains with an MIC up to
1 mg ⁄L, which included macrolide-susceptible
isolates and some mef(A)-containing isolates,
while survival was usually < 40% for erm(B)-
containing strains and with mef(A)-containing
strains where MICs were > 4 mg ⁄L (Fig. 2a) [22].
Azithromycin was also tested in this model, with
a PK ⁄PD breakpoint of £ 0.12 mg ⁄L determined,
which differentiated between macrolide-suscept-
ible strains and macrolide-resistant strains with
either resistance mechanism (Figure 2b) [22].
Clinical veriﬁcation of PK ⁄PD breakpoints for
macrolides is available for azithromycin from
double tympanocentesis studies in otitis media
[9,23]. In these studies, the rate of bacteriologi-
cal failure of azithromycin against strains of
S. pneumoniae with MICs > 0.25 mg ⁄L was 78.6%
(11 ⁄ 14 isolates) [9,23], a rate similar to the value
of 84% (48 ⁄ 57) obtained with placebo over
30 years ago [24]. In contrast, for strains of
Table 1. PK ⁄PD parameters predictive of antimicrobial efﬁcacy, based on unbound plasma levels [15–17]
Antimicrobial effect PK/PD parameter PK/PD target Antimicrobial class
Time-dependent killing
and minimal ⁄moderate
persistent effects
Proportion of dosing
interval for which unbound
serum drug level is above
MIC (T > MIC)
Unbound serum concentration
present for > 40–50% of the
dosing interval
Carbapenems
Cephalosporins
Monobactams
Oxazolidinones
Penicillins
Time-dependent killing
and prolonged
persistent effects
Unbound 24-h serum
AUC:MIC ratio
Unbound serum 24-h AUC:MIC
ratio > 25–30 (immunocompetent)
or > 100 (immunocompromised)
Streptogramins
Tetracyclines
Vancomycin
Erythromycina
Azithromycin
Clarithromycin
Clindamycin
Ketolidesb
Concentration-dependent
killing and prolonged
persistent effects
Unbound 24-h serum
AUC:MIC ratio or
peak:MIC ratio
Unbound serum 24-h AUC:MIC
ratio > 25–35 or peak:MIC > 3
(immunocompetent) or; unbound
serum 24-h AUC:MIC ratio > 100 or
Cmax:MIC > 10 (immunocompromised)
Fluoroquinolones
Aminoglycosides
aPlease see the main text for a discussion regarding the appropriate PK ⁄PD parameter for erythromycin and other
macrolides.
bTelithromycin has been shown to have concentration-dependent activity in vivo, but its PD parameters have not been
adequately established and may be different from other agents in this group [17].
20 Clinical Microbiology and Infection, Volume 10 Supplement 2, 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10 (Suppl. 2), 18–27
S. pneumoniae with azithromycin MICs of
£ 0.25 mg ⁄L, the bacteriological failure rate was
only 5.4% (2 ⁄ 37) [9,23]. These data indicate that
the clinically derived breakpoint for azithromycin
should be between 0.12 mg ⁄L and 1 mg ⁄L [25].
Against Haemophilus inﬂuenzae, for which most
azithromycin MICs are > 1 mg ⁄L, the bacterio-
logical failure rates in otitis media are again
similar to those of placebo for this species (61.7%
[50 ⁄ 81] vs. 52% [13 ⁄ 25], respectively) [9,23,24].
Thus, for azithromycin, the currently available
formulation would result in suboptimal bacterio-
logical efﬁcacy against S. pneumoniae with macro-
lide resistance associated with either erm or mef,
and against virtually all strains of H. inﬂuenzae
(Fig. 3) [26].
As discussed above, there are two major mech-
anisms of macrolide resistance among S. pneumo-
niae. The mef(A)-mediated efﬂux mechanism
(M-phenotype resistance) confers resistance to
macrolides but isolates remain susceptible to
clindamycin vs. the erm(B)-mediated methylation
mechanism (MLSB-phenotype resistance) for
which strains are resistant to both macrolides
and clindamycin. Strains possessing mef(A) have
erythromycin, azithromycin and clarithromycin
MICs of, typically, 2–16 mg ⁄L, whereas strains
with erm(B) have MICs as high as ‡ 256 mg ⁄L
[5,27–29]. For H. inﬂuenzae, MIC values for all the
macrolides and azalides are similar to those seen
in S. pneumoniae strains with efﬂux-mediated
resistance, and it is now known that a macrolide
efﬂux mechanism is present in the majority of
H. inﬂuenzae strains [5,30].
In animal models, it is possible to increase the
dose of macrolides and azalides to meet the
PK ⁄PD target for eradication of S. pneumoniae
strains with MICs in the range conferred by
mef(A) resistance and most strains of H. inﬂuenzae
[31]. In humans, however, limitations in PK are
combined with safety issues that arise with
increased dosages, making optimisation difﬁcult.
As a consequence, it is not possible to achieve
doses in humans that would meet the PK ⁄PD
target for eradication of these strains (Fig. 3) [26].
Options for the optimisation of macrolides and
azalides are therefore limited. Already, in areas of
high macrolide resistance prevalences, such as
Spain and the USA, clinical failures have been
seen in pneumococcal pneumonia for strains with
either mef(A) or erm(B) resistance mechanisms
[7,32]. Thus, if the prevalence of macrolide resist-
ance continues to increase, these agents will lose
even more of their clinical utility.
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Quinolones
The PK ⁄PD parameter predictive of quinolone
efﬁcacy is the unbound serum AUC:MIC ratio or
unbound serum Cmax:MIC ratio [18]. In animal
infection models, an AUC:MIC ratio of approxi-
mately 35 produces a bacteriostatic effect and this
is independent of the dosing interval, the site of
infection or the ﬂuoroquinolone agent used [18].
Mortality in animal models, for both Gram-
positive and Gram-negative infections, can be
prevented with AUC:MIC ratios of ‡ 100. Mortal-
ity in these models is > 50% for AUC:MIC ratios
of less than 30 [33]. In one of the very few PK ⁄PD
clinical studies ever conducted in humans where
levoﬂoxacin in respiratory tract and other infec-
tions was studied, clinical failure rates were 43%
for AUC:MIC ratios of < 25, 11.5% for AUC:MIC
ratios of 25–100 and 1% for ratios in excess of 100
[34]. For levoﬂoxacin, PK studies demonstrate
mean AUC values, which vary somewhat with
age and sex, of 47.5–74.7 mgÆh ⁄L (33.3–
52.3 mgÆh ⁄L based on free drug) for the 500 mg
daily dosing regimen and 90.7–110.0 mgÆh ⁄L
(63.5–77.0 mgÆh ⁄L based on free drug) for the
750 mg daily dosing regimen. These provide
PK ⁄PD breakpoints of 1.3–3.1 mg ⁄L for an
AUC:MIC target ratio of 25 and 0.3–0.7 mg ⁄L
(based on free drug values) for an AUC:MIC
target ratio of 100. A target AUC:MIC ratio of 25
is thought to be sufﬁcient for less severe infec-
tions in immunocompetent patients, while a
target AUC:MIC ratio of > 100 is needed for more
severe infections or for immunocompromised
patients [34,35]. The levoﬂoxacin MIC90 for
S. pneumoniae is 1 mg ⁄L [5], therefore > 90% of
isolates will be susceptible based on levoﬂoxacin
achieving AUC:MIC ratios of ‡ 25, but not based
on ratios of ‡ 100.
Fluoroquinolone resistance develops in a step-
wise fashion, through accumulation of mutations
in the quinolone resistance-determining regions
of DNA gyrase and topoisomerase IV. Currently,
there is little resistance to quinolones among
pneumococcal isolates, although this is increasing
in some regions [5,36]. Maintaining this low
prevalence of quinolone resistance is important,
because once a strain becomes resistant, the
activity of most, if not all, of the quinolones is
compromised. To meet PK ⁄PD targets for resist-
ant strains, the total daily dose would need to be
increased, which is best achieved by increasing
the single daily dose rather than increasing the
frequency of dosing, because quinolones are
concentration-dependent agents [18]. The ﬂuoro-
quinolones, however, have a relatively narrow
safety window, limiting the options for increasing
the dosage and frequency, and most currently
available agents would not be able to overcome
quinolone resistance in S. pneumoniae while still
maintaining acceptable safety ⁄ tolerability pro-
ﬁles. Where quinolone-resistant pneumococci do
exist, newer quinolones may be able to achieve
the necessary AUC:MIC ratio for one-eighth to
one-half of isolates with single-step mutations,
but the established and commonly used quinolo-
nes, ciproﬂoxacin and levoﬂoxacin, demonstrate
very little activity against any of these strains
[36,37]. In addition, despite the low prevalences of
quinolone resistance, clinical failures due to
quinolone resistance have been reported for lev-
oﬂoxacin, including the on-therapy selection of
resistant strains [8]. Thus, once a quinolone-
resistant strain becomes established in an area,
the clinical value of the quinolones becomes
questionable.
b-Lactams
All b-lactams display time-dependent bacterio-
logical activity, so the T > MIC is the relevant
PK ⁄PD parameter [18]. In animal models of
S. pneumoniae infection, a T > MIC of 40–50% of
the dosing interval is required to prevent mortal-
ity for cephalosporins and > 40% for penicillins
[38]. Clinical studies in otitis media and sinusitis
also show maximal bacterial eradication with
T > MIC values > 40% [39].
Increases in penicillin resistance in S. pneumo-
niae world-wide are of concern [5]. A recent
case–control study by Ailani et al. found that
cephalosporin resistance in S. pneumoniae in-
creased the time required to respond to treat-
ment and the length of hospital stay [40]. There
were no differences, however, in mortality in this
study between patients with cephalosporin-
susceptible vs. -resistant strains [40]. For the oral
cephalosporins, limitations in PK, primarily the
lack of linear PK, prevent the possibility of
sufﬁciently increasing T > MIC to cover penicil-
lin-resistant strains by increasing dosing or
dosing frequency. A study by Urban et al. eval-
uated dosing of cefpodoxime in the mouse thigh
model with S. pneumoniae [41]. In this model, it
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was possible to increase doses of cefpodoxime to
cover strains with an MIC of ‡ 1 mg ⁄L for ‡ 30%
of the dosing interval. However, the doses
necessary to reach this level of coverage would
not be achievable in humans (Figure 4) [41,42].
Cefaclor provides another example of the difﬁ-
culties in achieving the necessary T > MIC with
some cephalosporins. Although the peak concen-
tration of cefaclor provided by the standard
twice daily and three times daily dosing regi-
mens is 13 mg ⁄L, the very short half-life of this
drug means that the concentration present for
40–50% of the dosing interval is only 0.5 mg ⁄L.
With a PK ⁄PD breakpoint of 0.5 mg ⁄L, cefaclor
can only reliably cover the most sensitive peni-
cillin-susceptible strains of S. pneumoniae,
whereas penicillin-intermediate and -resistant
S. pneumoniae and H. inﬂuenzae and Moraxella
catarrhalis are not covered at this breakpoint
(Figure 5) [43,44]. The low efﬁcacy for cefaclor
predicted by this PK ⁄PD breakpoint has been
borne out in clinical studies in otitis media, in
which cefaclor was shown to have failure rates
similar to those of placebo against penicillin-
intermediate and -resistant S. pneumoniae and
H. inﬂuenzae [25].
For penicillin given at high doses intraven-
ously, there is still no proven case of failure in
pneumococcal pneumonia due to penicillin resist-
ance and no strong evidence for an effect of
penicillin resistance on patient outcomes [32]. The
main reason for this is that penicillin can be given
at very high doses, extending the T > MIC and
therefore covering ‘resistant’ pathogens. Thus,
unlike other classes of antimicrobial, optimising
the PK by increasing T > MIC is possible with the
penicillins, including oral agents such as amoxi-
cillin, by increasing the dose, increasing the
dosing frequency or enhancing the PK by other
means.
DEVELOPMENT OF A
PHARMACOKINETICALLY
ENHANCED FORMULATION OF
AMOXICILLIN ⁄ CLAVULANATE
The standard adult dose of amoxicillin ⁄ clavula-
nate in many countries is 875 ⁄ 125 mg, given twice
daily. At this dose, the peak amoxicillin concen-
tration is similar to that of cefaclor, at 12 mg ⁄L,
but at least 2 mg ⁄L of amoxicillin is present for
‡ 40% of the dosing interval (Fig. 6, Table 2)
[13,44–46]. For S. pneumoniae, a PK ⁄PD breakpoint
of 2 mg ⁄L for amoxicillin ⁄ clavulanate covers all
penicillin-susceptible strains with approximately
a 100-fold safety margin. This formulation is also
effective against penicillin-intermediate strains
and some, but not all, penicillin-resistant strains.
This breakpoint is also above the MIC90 for
H. inﬂuenzae and M. catarrhalis, and the clavula-
nate provides coverage of b-lactamase-positive
strains. Despite the coverage achieved with the
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currently available dosage of amoxicillin ⁄ clavul-
anate, penicillin-resistant S. pneumoniae are
becoming more common, including strains with
amoxicillin MICs of > 2 mg ⁄L [5]. With the
875 ⁄ 125 mg twice daily standard dose of amox-
icillin ⁄ clavulanate, the T > MIC is only 26% of
the dosing interval for bacterial strains with
amoxicillin MICs of 4 mg ⁄L (Table 2) [13,46].
The PK ⁄PD characteristics of amoxicillin ⁄ cla-
vulanate are well known [46]. In order to
develop a new formulation that would maximise
eradication and, therefore, efﬁcacy against peni-
cillin-resistant S. pneumoniae, a target T > MIC of
> 40% was set for strains with amoxicillin MICs
of 4 mg ⁄L. In order to achieve this, there was a
number of issues that had to be considered.
Increasing the T > MIC by simply increasing the
dose of amoxicillin ⁄ clavulanate is possible for
intravenous or suspension formulations, but for
the tablet form there are constraints for tablet
size or the number of tablets that a patient can
take at a time. Increasing the peak serum
concentrations may also increase the number of
adverse events patients experience. PK could
also be improved by increasing the dosing
frequency. This approach has already been
adopted in Spain with the 875 ⁄ 125 mg three
times daily formulation, and in France with a
1000 ⁄ 125 mg formulation being administered
twice daily for acute exacerbations of chronic
bronchitis and three times daily for CAP, in
response to recommendations in these countries
for amoxicillin use (Table 2) [46]. However,
maintaining the convenience of a twice daily
dosing schedule would be desirable. Finally, the
amount of clavulanate must be maintained at a
level where it provides coverage of b-lactamases,
but not so high as to increase the potential for
gastrointestinal side-effects of this compound.
The question then arises of just how the
T > MIC can be extended to cover strains with
amoxicillin MICs > 2 mg ⁄L while maintaining a
twice daily dosing schedule, b-lactamase cover-
age and an adverse event proﬁle similar to that of
conventional formulations. This question was
addressed by developing a novel form of bilayer
tablet containing an immediate-release amoxicil-
lin ⁄ clavulanate layer and a sustained-release
amoxicillin layer. The immediate-release portion
of the tablet contains amoxicillin trihydrate equiv-
alent to 562.5 mg of amoxicillin and potassium
clavulanate equivalent to 62.5 mg of clavulanic
acid [45]. The sustained-release layer contains
crystalline sodium amoxicillin equivalent to
437.5 mg of amoxicillin, which has a longer
half-life than the trihydrate. This new pharma-
cokinetically enhanced 2000 ⁄ 125 mg amoxicil-
lin ⁄ formulation is given as two tablets twice
daily [45]. As for the majority of oral formula-
tions, the unit dose of clavulanate has remained
125 mg in the new formulation, this amount being
sufﬁcient to inhibit the clinically relevant target
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Table 2. T > MIC (as percentage of dosing interval)
achieved with four amoxicillin ⁄ clavulanate formulations
[13,45,46]
Amoxicillin/clavulanate
formulation
T > MIC (% of dosing
interval) for
amoxicillin MIC (mg/L):
1 2 4 8
875 ⁄ 125 mg twice daily 44 40 26 –
875 ⁄ 125 mg three
times daily
69 57 34 –
1000 ⁄ 125 mg three
times daily
> 65 55 41 –
2000 ⁄ 125 mg twice dailya > 70 60 49 35
aAmoxicillin component contains immediate-release amox-
icillin trihydrate equivalent to 562.5 mg amoxicillin and
sustained-release crystalline sodium amoxicillin equival-
ent to 437.5 mg amoxicillin.
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b-lactamases and protect the amoxicillin compo-
nent [47]. Although clavulanate does have some
antibacterial activity in vitro, the addition of
clavulanate does not affect the PK ⁄PD proﬁle of
amoxicillin against S. pneumoniae [48]. Amoxicil-
lin ⁄ clavulanate 2000 ⁄ 125 mg twice daily achieves
a peak concentration of amoxicillin similar to
conventional formulations [45]. Due to the sus-
tained-release amoxicillin component, however,
the decline in concentration over time is not as
steep as conventional formulations, thus enhan-
cing the PK and extending the T > MIC to 49% of
the dosing interval for strains with amoxicillin
MICs of 4 mg ⁄L and 35% for strains with MICs of
8 mg ⁄L (Figures 7 and 8, Table 2) [13,44–46]. In
contrast, just increasing the dose of amoxicillin to
2000 mg, all immediate-release, would only
achieve a T > MIC of 35% against strains with
amoxicillin MICs of 4 mg ⁄L (Figure 8) [13,45].
CONCLUSIONS
Many currently available antimicrobial agents, or
currently available formulations of these agents,
do not have adequate PK ⁄PD to achieve bacterial
eradication of common respiratory pathogens,
including antibacterial-resistant strains. The pre-
valence of antimicrobial resistance is increasing
world-wide, therefore new agents designed
speciﬁcally to target these organisms are needed.
It is unlikely, however, that any new antibac-
terials with substantially increased efﬁcacy
against resistant respiratory pathogens are to
become available in the short or medium term.
PK ⁄PD parameters are predictive of bacterio-
logical and clinical outcomes, and can be used to
optimise antibacterial dosing regimens. PK ⁄PD
parameters can also be used in the formulation
of new antimicrobials to combat resistant path-
ogens and the continuing evaluation of currently
available agents. Animal models have demon-
strated the predictive value of PK ⁄PD parame-
ters, and clinical studies, such as those in otitis
media, have conﬁrmed that these PK ⁄PD param-
eters are also valid predictors of efﬁcacy in
humans [15,25].
Designed using PK ⁄PD targets, a new formu-
lation of amoxicillin ⁄ clavulanate (2000 ⁄ 125 mg
twice daily) has been developed as a novel bilayer
tablet incorporating sustained-release technology
[45]. This new formulation achieves a mean T >
MIC of 49% of the 12-h dosing interval for
amoxicillin MICs of 4 mg ⁄L [45]. This is predic-
tive of high bacteriological efﬁcacy against not
only penicillin-susceptible and -intermediate
strains of S. pneumoniae, but also against the
majority of penicillin-resistant strains [46]. The
combination of amoxicillin with clavulanate en-
sures coverage of b-lactamase-producing H. inﬂu-
enzae and M. catarrhalis [47]. Clinical trials of this
new pharmacokinetically enhanced formulation
of amoxicillin ⁄ clavulanate in a variety of
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respiratory illnesses, including those caused by
resistant strains, are reviewed in this issue (see
Garau, this issue) [49–52].
Utilizing PK ⁄PD represents an effective way of
optimising currently available antibacterials, thus
retaining our ability to treat difﬁcult pathogens
such as penicillin-resistant S. pneumoniae in an
environment of increasing antibacterial resistance.
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